Brought to you by 
Innovent Biologics raises $260mm in Series D round
06 Dec 2016
Executive Summary
Chinese biopharma Innovent Biologics Inc. raised $260mm in its Series D financing round led by PE fund Future Industry Investment Fund (managed by SDIC Fund Management; subsidiary of State Development & Investment Corp). China Life Private Equity, Milestone, Ping An, and Taikang Insurance group also participated and joined existing investors Legend Capital, Temasek, and Hillhouse Capital. Innovent will use the proceeds to fund its biologics pipeline which includes 12 candidates for cancer, autoimmune, ophthalmology, and cardiovascular diseases. The Series D round is the largest ever for biopharma in China and one of the largest worldwide across pharma in 2016. The company has now raised over $385mm to date.
Deal Industry
- Pharmaceuticals
- Services
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Innovent Biologics raises $260mm in Series D round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice